Personalized alloreactive cellular immunotherapy platform based on Activated Targeted Alloreactive Killer cells (ATACK), developed from earlier IMAK concepts and enhanced with monoclonal antibody targeting of overexpressed tumor antigens.
atack intentionally-mismatched-donor-lymphocytes activated-killer-cells donor-lymphocytes monoclonal-antibody-targeting imak
-
Updated
Feb 16, 2026